Sputum

Janssen Research & Development has partnered with the International Union Against Tuberculosis and Lung Disease (The Union) to include Sirturo (bedaquiline) in the Stream study.

The Stream study is an ongoing, multi-centre international randomised controlled study to assess a standardised treatment regimen of anti-tuberculosis drugs for patients with multidrug-resistant tuberculosis (MDR-TB).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Bedaquiline is a diarylquinoline antimycobacterial drug, indicated as part of a combination therapy in adults with pulmonary MDR-TB.

Janssen noted it is working with The Union and the trial’s principal investigators from the UK Medical Research Council (MRC) on an amendment to their current protocol and to evaluate a new treatment regimen, including an all-oral option.

"Sirturo received accelerated approval in the US, conditional approval in the EU, and approval in South Korea, South Africa and the Philippines."

The amendment, including two bedaquiline-containing treatment arms, will be known as Stream 2. It is part of the post-approval requirements for bedaquiline from both US Food and Drug Administration (FDA) and European Medicines Agency (EMA), and is accepted as an alternative to the initially planned Phase III trial of Sirturo.

See Also:

Sirturo received accelerated approval in the US, conditional approval in the European Union, in addition to approval in South Korea, South Africa and the Philippines.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It is registered in the Russian Federation through a partner for the Russian Federation and Commonwealth of Independent States (CIS), JSC Pharmstandard.

The company filed regulatory applications in China, Colombia, India, Peru, Thailand and Vietnam.

Image: Photomicrograph of a sputum sample containing Mycobacterium tuberculosis. Photo: courtesy of CDC/ TimVickers/ Bawolff.